Purchase this article with an account.
In Boem Chang, Jae Yong Park, Jae Suk Kim; Clinical Application of Matrix Metalloproteinase 9 Test Using Immunoassay Kit. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4858.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the clinical usefulness of InflammaDry, which measures matrix metalloproteinase 9 (MMP-9) in the tear film, at the time of diagnosis and during follow up period in patients with dry eye disease (DED).
Both eyes of patients with DED were included. The tear film was analyzed for MMP-9 by a commercially available test (InflammaDry; Rapid Pathogen Screening, Inc, Sarasota, FL) detecting levels of more than 40ng/ml. Ocular surface disease index (OSDI) score, corneal staining, tear film break-up time (TBUT) and Schirmer test results were also evaluated. These findings were correlated to results of the MMP-9 test. After the evaluation, cyclosporine 0.5mg/mL was administered twice a day and the results were compared one month later by repeating the above tests.
78 eyes of 39 patients were included, and 42 eyes of 21 patients were evaluated the same tests after 1 month. In 63 eyes (80.8%) of 78 eyes, the MMP-9 results were positive. In 34 eyes (80.9%) positive for MMP-9 before administered cyclosporine 0.5mg/mL, levels of MMP-9 were decreased (p=0.001), improved corneal erosion (p<0.001), increased TBUT (p<0.001) and improved Schirmer test was also improved (p=0.014) after administered cyclosporine 0.5mg/mL for 1 month. In contrast, 8 eyes (19.1%) were negative for MMP-9 before administered cyclosporine 0.5mg/mL, levels of MMP-9 were increased(p=0.020) after use of cyclosporine 0.5mg/mL for 1 month. Corneal staining, TBUT and Schirmer test results were not significantly different from the before using cyclosporine.
If the InflammaDry test is positive in the patients with DED, treatment with cyclosporine will be more effective. So, performing an InflammaDry test before beginning cyclosporine therapy may be helpful in predicting prognosis.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only